Intravitreal bevacizumab in a patient with a macular star in malignant hypertension

Eur J Ophthalmol. 2011 May-Jun;21(3):336-9. doi: 10.5301/EJO.2010.5819.

Abstract

Purpose: To report a case of retinopathy secondary to malignant hypertension showing a macular star, which responded favorably to a single intravitreal injection of bevacizumab (IVB).

Methods: A 46-year-old man with malignant hypertension showing incomplete macular star in his right eye with best-corrected visual acuity (BCVA) of 20/32 underwent IVB.

Results: Subsequent examinations revealed a progressive resolution of the macular star with functional recovery over the follow-up. In particular, at the 9-month examination BCVA was 20/20, fundus biomicroscopy disclosed resolution of the macular star, and the retinal sensitivity improved remarkably.

Conclusions: Intravitreal injection of bevacizumab can be a useful approach to treat the exudative manifestations of malignant hypertension.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Blood Pressure / physiology
  • Fluorescein Angiography
  • Humans
  • Hypertension, Malignant / complications*
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Retinal Diseases / diagnosis
  • Retinal Diseases / drug therapy*
  • Retinal Diseases / etiology*
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab